LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

AZN

200.79

-1.4%↓

Home・Akcijų sąrašas・Savara Inc

Savara Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

5.55 -7.81

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

5.55

Max

5.99

Pagrindiniai rodikliai
By Trading Economics
Pajamos	840K -30M
Pelnas, tenkantis vienai akcijai	-0.14
Darbuotojai	59
EBITDA	841K -29M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+70.55% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-26

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	418M 1.2B
Ankstesnė atidarymo kaina	13.36
Ankstesnė uždarymo kaina	5.55

Naujienos nuotaikos

By Acuity

40%

60%

122 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

2.76 / 2.84 Palaikymas ir pasipriešinimas

Savara Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-03 18:43; UTC

Svarbiausios naujienos

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

2026-03-03 17:33; UTC

Įsigijimai, susijungimai, perėmimai

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

2026-03-03 23:45; UTC

Rinkos pokalbiai

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

2026-03-03 23:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

2026-03-03 23:25; UTC

Rinkos pokalbiai

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

2026-03-03 23:25; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-03-03 22:38; UTC

Svarbiausios naujienos

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

2026-03-03 22:16; UTC

Uždarbis

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

2026-03-03 22:09; UTC

Uždarbis

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

2026-03-03 22:06; UTC

Uždarbis

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

2026-03-03 22:05; UTC

Uždarbis

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

2026-03-03 22:03; UTC

Uždarbis

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

2026-03-03 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Tech, Media & Telecom Roundup: Market Talk

2026-03-03 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-03 21:45; UTC

Svarbiausios naujienos

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

2026-03-03 21:37; UTC

Uždarbis

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

2026-03-03 21:26; UTC

Svarbiausios naujienos

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

2026-03-03 20:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

2026-03-03 20:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

2026-03-03 19:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold and Silver Drop as Energy Surges -- Market Talk

2026-03-03 18:43; UTC

Uždarbis

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

2026-03-03 18:29; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Energy Roundup: Market Talk

2026-03-03 18:29; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

2026-03-03 18:22; UTC

Svarbiausios naujienos

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

2026-03-03 18:22; UTC

Svarbiausios naujienos

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

2026-03-03 18:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

2026-03-03 18:14; UTC

Uždarbis

How Long Can Anthropic Play Defense? -- WSJ

2026-03-03 17:41; UTC

Svarbiausios naujienos

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

2026-03-03 17:36; UTC

Svarbiausios naujienos

Iran Conflict is Starting to Boost Gasoline Prices -- Update

2026-03-03 17:28; UTC

Įsigijimai, susijungimai, perėmimai

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Akcijų palyginimas

Kainos pokytis

Savara Inc Prognozė

Kainos tikslas

By TipRanks

70.55% į viršų

12 mėnesių prognozė

Vidutinis 10.25 USD 70.55%

Aukščiausias 11 USD

Žemiausias 9 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Savara Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Savara Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

2.76 / 2.84Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

All events are bullish.

Bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

122 / 352 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.